scholarly journals Varicella-Zoster Virus Activates Inflammatory Cytokines in Human Monocytes and Macrophages via Toll-Like Receptor 2

2005 ◽  
Vol 79 (20) ◽  
pp. 12658-12666 ◽  
Author(s):  
Jennifer P. Wang ◽  
Evelyn A. Kurt-Jones ◽  
Ok S. Shin ◽  
Michael D. Manchak ◽  
Myron J. Levin ◽  
...  

ABSTRACT The pattern recognition receptor Toll-like receptor 2 (TLR2) has been implicated in the response to several human viruses, including herpes simplex viruses (types 1 and 2) and cytomegalovirus. We demonstrated that varicella-zoster virus (VZV) activates inflammatory cytokine responses via TLR2. VZV specifically induced interleukin-6 (IL-6) in human monocytes via TLR2-dependent activation of NF-κB, and small interfering RNA designed to suppress TLR2 mRNA reduced the IL-6 response to VZV in human monocyte-derived macrophages. Unlike other herpesviruses, the cytokine response to VZV was species specific. VZV did not induce cytokines in murine embryonic fibroblasts or in a mouse cell line, although VZV did activate NF-κB in a human cell line expressing a murine TLR2 construct. Together, these results suggest that TLR2 may play a role in the inflammatory response to VZV infection.

2017 ◽  
Vol 1 (26) ◽  
pp. 2510-2519 ◽  
Author(s):  
Defne Bayik ◽  
Debra Tross ◽  
Lydia A. Haile ◽  
Daniela Verthelyi ◽  
Dennis M. Klinman

Key Points NF-κB and Akt regulate human monocyte into macrophage differentiation; p38 MAPK and PTGS2 promote the generation of suppressive macrophage. The Toll-like receptor 2/1 agonist PAM3 induces human monocytes to mature into immunosuppressive macrophages in vitro and in vivo.


2015 ◽  
Vol 89 (14) ◽  
pp. 7133-7146 ◽  
Author(s):  
Peter Norberg ◽  
Daniel P. Depledge ◽  
Samit Kundu ◽  
Claire Atkinson ◽  
Julianne Brown ◽  
...  

ABSTRACTVaricella-zoster virus (VZV) is a human herpesvirus, which during primary infection typically causes varicella (chicken pox) and establishes lifelong latency in sensory and autonomic ganglia. Later in life, the virus may reactivate to cause herpes zoster (HZ; also known as shingles). To prevent these diseases, a live-attenuated heterogeneous vaccine preparation, vOka, is used routinely in many countries worldwide. Recent studies of another alphaherpesvirus, infectious laryngotracheitis virus, demonstrate that live-attenuated vaccine strains can recombinein vivo, creating virulent progeny. These findings raised concerns about using attenuated herpesvirus vaccines under conditions that favor recombination. To investigate whether VZV may undergo recombination, which is a prerequisite for VZV vaccination to create such conditions, we here analyzed 115 complete VZV genomes. Our results demonstrate that recombination occurs frequently for VZV. It thus seems that VZV is fully capable of recombination if given the opportunity, which may have important implications for continued VZV vaccination. Although no interclade vaccine-wild-type recombinant strains were found, intraclade recombinants were frequently detected in clade 2, which harbors the vaccine strains, suggesting that the vaccine strains have already been involved in recombination events, eitherin vivoorin vitroduring passages in cell culture. Finally, previous partial and complete genomic studies have described strains that do not cluster phylogenetically to any of the five established clades. The additional VZV strains sequenced here, in combination with those previously published, have enabled us to formally define a novel sixth VZV clade.IMPORTANCEAlthough genetic recombination has been demonstrated to frequently occur for other human alphaherpesviruses, herpes simplex viruses 1 and 2, only a few ancient and isolated recent recombination events have hitherto been demonstrated for VZV. In the present study, we demonstrate that VZV also frequently undergoes genetic recombination, including strains belonging to the clade containing the vOKA strain.


Sign in / Sign up

Export Citation Format

Share Document